Thursday, March 28, 2019
Latest News
- Sanofi
Thursday, March 21, 2019
Lead Pharma Begins Phase I Trials with SAR441169 Candidate Treatment for Psoriasis
Lead Pharma, a pharmaceutical company developing innovative medicines for the treatment of immunological and oncological indications, achieved a fourth milestone under its license & collaboration …
Read the full story
Monday, March 11, 2019
FDA Approves Dupixent for Moderate to Severe AD in Adolescents
The FDA has approved expanded use of Regeneron Pharmaceuticals Inc and Sanofi SA's eczema drug Dupixent to include patients aged 12 through 17 whose disease is not adequately controlled with topic…
Read the full storyTuesday, November 06, 2018
US FDA Grants Dupixent Priority Review for Moderate-to-Severe AD in Adolescents
The US Food and Drug Administration (FDA) has granted Priority Review for Dupixent (dupilumab) as a potential treatment for adolescents with uncontrolled moderate-to-severe atopic dermatitis (AD). …
Read the full storyWednesday, May 16, 2018
Dupixent Improves Moderate-to-Severe Atopic Dermatitis in Adolescents
DUPIXENT (dupilumab) performed well in a Phase 3 Trial of inadequately controlled moderate-to-severe atopic dermatitis in adolescents, Regeneron and Sanofi report. In the trial, treatment with…
Read the full storyTuesday, May 01, 2018
FDA Agrees to Priority Review of Cemiplimab for Advanced Squamous Cell Carcinoma
The FDA has accepted the Biologics License Application (BLA) for cemiplimab for the treatment of patients with metastatic cutaneous squamous cell carcinoma (CSCC) or patients with locally advance…
Read the full story
Tuesday, February 20, 2018
Asthma and Allergy Foundation Study Shows High Prevalence and QoL Impact for Adults with Atopic Dermatitis
The Asthma and Allergy Foundation of America (AAFA) shared data demonstrating the high rate of prevalence of atopic dermatitis (AD) in the US adult population and a greater impact on health-related qu…
Read the full storyWednesday, January 17, 2018
GlobalData: Promising Future Forecasted for Dupixent
Regeneron Pharmaceuticals and Sanofi Genzyme’s Dupixent is currently the most successful biologic treatment for moderate-to-severe atopic dermatitis on the market, according to GlobalData. Th…
Read the full storyMonday, September 18, 2017
EADV News: Positive Study Results for Dupixent® (dupilumab) in Patients With Moderate-to-Severe AD
Dupixent with topical corticosteroids (TCS) significantly improved measures of overall disease severity, skin clearing, itching, and patient reported quality of life measure in adults with moderate-to…
Read the full storyFriday, September 08, 2017
Cemiplimab Receives FDA Breakthrough Therapy Designation for Advanced Cutaneous Squamous Cell Carcinoma
The FDA has granted Breakthrough Therapy designation status to Regeneron Pharmaceuticals, Inc. and Sanofi's cemiplimab (REGN2810) for the treatment of adults with metastatic cutaneous squamou…
Read the full story
Tuesday, March 28, 2017
FDA Approves New Eczema Drug Dupixent
The FDA has approved Dupixent (dupilumab) injection to treat adults with moderate-to-severe eczema (atopic dermatitis). Regeneron Pharmaceuticals, Inc.'s Dupixent is intended for patients whose ec…
Read the full storyWednesday, October 05, 2016
New Survey: AD Is More Than Skin Deep
American adults with atopic dermatitis (AD) report issues with sleep, ability to work and feelings of depression and anxiety, a new survey shows. The findings are significant for clinicians, such as N…
Read the full storyMonday, October 03, 2016
Regeneron and Sanofi's AD Drug Dupilumab Performs Well in Phase III Studies
Dupilumab improves the signs and symptoms of atopic dermatitis including pruritus, anxiety/depression symptoms, and quality of life, according to two Phase III clinical trials published in t…
Read the full storyMonday, September 26, 2016
Regeneron and Sanofi's Dupilumab Biologics License Application Accepted for Priority Review by FDA
The FDA has accepted for priority review the Biologics License Application (BLA) for dupilumab from Regeneron Pharmaceuticals, Inc. and Sanofi for the treatment of adult patients with inadequately con…
Read the full storyMonday, June 06, 2016
Dupilumab with Topical Corticosteroids (TCS) Superior to TCS Alone in Long-term Atopic Dermatitis Study
Treatment with investigational dupilumab in combination with topical corticosteroids (TCS) significantly improved measures of overall disease severity, according to one-year results of the LIBERTY AD …
Read the full storyFriday, April 01, 2016
Next Stop FDA Approval? Dupilumab Improves Symptoms in Moderate-to-Severe AD
Dupilumab helps improve the signs and symptoms of moderate-to-severe atopic dermatitis (AD) in adults, according to two late stage clinical trials. The U.S. Food and Drug Administration (FDA) grant…
Read the full story
